Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
Atsushi Tanaka,Isao Taguchi,Itaru Hisauchi,Hisako Yoshida,Michio Shimabukuro,Hiroshi Hongo,Tetsuya Ishikawa,Toshiaki Kadokami,Shusuke Yagi,Masataka Sata,Koichi Node,DIANA study investigators,Machiko Asaka,Kohei Kamishita,Tetsuya Kaneko,Kohei Kaneta,Masahiro Natsuaki,Aya Shiraki,Shinjo Sonoda,Motoko Tago,Ayumu Yajima,Kensuke Yokoi,Goro Yoshioka,Ryo Nakamura,Junichiro Nishi,Ken Onizuka,Takayuki Ise,Muneyuki Kadota,Yutaka Kawabata,Kenya Kusunose,Kazuhisa Matsumoto,Tomomi Matsuura,Yuichiro Okushi,Hiromitsu Seno,Takeshi Soeki,Kumiko Suto,Tomonori Takahashi,Takeshi Tobiume,Tetsuzo Wakatsuki,Hirotsugu Yamada,Koji Yamaguchi,Yuki Hotta,Mariko Iwasaki,Junichiro Kazama,Yu Saito,Masahiro Sato,Yoshinori Takiguchi,Hayato Tanabe,Kiriko Watanabe,Mizuki Yamaguchi,Sachiko Tomita,Mikiko Kagiyama,Keiko Onodera
DOI: https://doi.org/10.1186/s40001-023-01208-1
2023-07-17
Abstract:Introduction: Dotinurad is a newer urate-lowering agent that selectively inhibits urate transporter 1 in the renal proximal tubule and increases urinary urate excretion. Currently, little is known about the clinical efficacies of dotinurad in patients with hyperuricemia and hypertension. The aim of this study was to assess the clinical effects of a selective urate reabsorption inhibitor dotinurad on serum uric acid (SUA) levels and relevant vascular markers in patients with hyperuricemia and treated hypertension. Methods: This investigator-initiated, multicenter, prospective, single-arm, open-label, exploratory clinical trial in Japan enrolled patients with hyperuricemia and treated hypertension who received a 24-week dotinurad therapy (a starting dose at 0.5 mg once daily and up-titrated to 2 mg once daily). The primary endpoint was a percentage change in the SUA level from baseline to week 24. The secondary endpoints were cardiovascular and metabolic measurements, including changes in the cardio-ankle vascular index (CAVI) and derivatives of reactive oxygen metabolites (d-ROMs) concentration at week 24. Results: Fifty patients (mean age 70.5 ± 11.0 years, with 76.0% being men, and mean SUA level 8.5 ± 1.2 mg/dL) were included in the analysis. The percentage change from baseline in the SUA level at week 24 was - 35.8% (95% confidence interval [CI] - 39.7% to - 32.0%, P < 0.001), with approximately three quarters of patients achieving an SUA level of ≤ 6.0 mg/dL at week 24. The proportional changes from baseline in the geometric mean of CAVI and d-ROMs at week 24 were 0.96 (95% CI 0.92 to 1.00, P = 0.044) and 0.96 (95% CI 0.92 to 1.00, P = 0.044), respectively. Conclusion: In addition to meaningful SUA-lowering effects, 24 weeks of dotinurad therapy may favorably affect arterial stiffness and oxidative stress markers, suggesting off-target vascular protection of dotinurad. Further research is expected to verify our findings and elucidate the entire off-target effects of dotinurad. Trial registration jRCTs021210013, registration date June 24, 2021.